vs
Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $75.1M, roughly 1.2× SAUL CENTERS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 10.6%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.2%).
Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
BFS vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $86.8M |
| Net Profit | $6.5M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 65.4% | -84.7% |
| Net Margin | 8.7% | — |
| Revenue YoY | 10.6% | 17.7% |
| Net Profit YoY | -19.6% | — |
| EPS (diluted) | $0.15 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $86.8M | ||
| Q3 25 | $72.0M | $67.5M | ||
| Q2 25 | $70.8M | $60.0M | ||
| Q1 25 | $71.9M | $49.3M | ||
| Q4 24 | $67.9M | $73.7M | ||
| Q3 24 | $67.3M | $58.6M | ||
| Q2 24 | $66.9M | $31.1M | ||
| Q1 24 | $66.7M | $715.0K |
| Q4 25 | $6.5M | — | ||
| Q3 25 | $10.5M | $-91.3M | ||
| Q2 25 | $10.7M | $-111.7M | ||
| Q1 25 | $9.8M | $-116.2M | ||
| Q4 24 | $8.1M | — | ||
| Q3 24 | $14.5M | $-83.5M | ||
| Q2 24 | $14.4M | $-97.1M | ||
| Q1 24 | $13.6M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | 73.6% | 46.2% | ||
| Q2 24 | 74.2% | -0.8% | ||
| Q1 24 | 72.8% | — |
| Q4 25 | 65.4% | -84.7% | ||
| Q3 25 | 69.1% | -140.7% | ||
| Q2 25 | 68.7% | -189.8% | ||
| Q1 25 | 66.5% | -245.8% | ||
| Q4 24 | 82.9% | -117.5% | ||
| Q3 24 | 72.8% | -152.1% | ||
| Q2 24 | 75.0% | -327.6% | ||
| Q1 24 | 72.4% | -16464.6% |
| Q4 25 | 8.7% | — | ||
| Q3 25 | 14.6% | -135.3% | ||
| Q2 25 | 15.1% | -186.2% | ||
| Q1 25 | 13.6% | -235.5% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 21.5% | -142.7% | ||
| Q2 24 | 21.6% | -312.2% | ||
| Q1 24 | 20.4% | -15800.8% |
| Q4 25 | $0.15 | — | ||
| Q3 25 | $0.32 | — | ||
| Q2 25 | $0.33 | $-0.33 | ||
| Q1 25 | $0.29 | $-0.36 | ||
| Q4 24 | $0.22 | $-0.24 | ||
| Q3 24 | $0.48 | $-0.28 | ||
| Q2 24 | $0.48 | $-0.34 | ||
| Q1 24 | $0.45 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.7M | $297.0M |
| Total DebtLower is stronger | $468.4M | — |
| Stockholders' EquityBook value | $307.8M | $698.6M |
| Total Assets | $2.2B | $913.2M |
| Debt / EquityLower = less leverage | 1.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.7M | $297.0M | ||
| Q3 25 | $11.8M | $300.8M | ||
| Q2 25 | $5.3M | $301.2M | ||
| Q1 25 | $6.5M | $359.7M | ||
| Q4 24 | $10.3M | $323.8M | ||
| Q3 24 | $7.2M | $397.5M | ||
| Q2 24 | $6.9M | $412.5M | ||
| Q1 24 | $7.1M | $356.2M |
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $307.8M | $698.6M | ||
| Q3 25 | $316.6M | $702.3M | ||
| Q2 25 | $322.4M | $698.5M | ||
| Q1 25 | $328.4M | $767.9M | ||
| Q4 24 | $335.8M | $710.4M | ||
| Q3 24 | $341.8M | $773.5M | ||
| Q2 24 | $345.7M | $768.5M | ||
| Q1 24 | $347.1M | $680.0M |
| Q4 25 | $2.2B | $913.2M | ||
| Q3 25 | $2.2B | $904.9M | ||
| Q2 25 | $2.1B | $907.4M | ||
| Q1 25 | $2.1B | $966.7M | ||
| Q4 24 | $2.1B | $910.4M | ||
| Q3 24 | $2.1B | $991.1M | ||
| Q2 24 | $2.1B | $964.3M | ||
| Q1 24 | $2.0B | $869.8M |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.8M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | 15.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.8M | $-52.6M | ||
| Q3 25 | $20.6M | $-78.7M | ||
| Q2 25 | $26.6M | $-67.4M | ||
| Q1 25 | $30.4M | $-103.7M | ||
| Q4 24 | $121.2M | $-73.3M | ||
| Q3 24 | $26.5M | $-59.0M | ||
| Q2 24 | $32.1M | $-98.4M | ||
| Q1 24 | $33.8M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | $-28.3M | $-61.3M | ||
| Q2 24 | $-12.5M | $-98.9M | ||
| Q1 24 | $-11.7M | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | -42.1% | -104.6% | ||
| Q2 24 | -18.7% | -317.9% | ||
| Q1 24 | -17.6% | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 81.5% | 3.9% | ||
| Q2 24 | 66.7% | 1.4% | ||
| Q1 24 | 68.3% | 583.4% |
| Q4 25 | 15.35× | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFS
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
